One    O
study    O
noted    O
the    O
use    O
of    O
panobinostat    B-Antineoplastic102722458
,    O
entinostat    O
,    O
romidepsin    B-Antineoplastic102722458
,    O
and    O
vorinostat    B-Antineoplastic102722458
specifically    O
for    O
the    O
purpose    O
of    O
reactivating    O
latent    O
HIV    O
in    O
order    O
to    O
diminish    O
the    O
reservoirs    O
.    O

Romidepsin    B-Antineoplastic102722458
(    O
trade    O
name    O
Istodax    O
)    O
was    O
licensed    O
by    O
the    O
US    O
FDA    O
in    O
Nov    O
2009    O
for    O
cutaneous    O
T    O
-    O
cell    O
lymphoma    O
(    O
CTCL    O
)    O
.    O

erbulozole    B-Antineoplastic102722458
(    O
INN    O
)    O

Prior    O
to    O
the    O
introduction    O
of    O
the    O
newer    O
enzalutamide    B-Antineoplastic102722458
in    O
2012    O
,    O
bicalutamide    O
was    O
considered    O
to    O
be    O
the    O
standard    O
-    O
of    O
-    O
care    O
antiandrogen    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
,    O
and    O
still    O
remains    O
widely    O
used    O
for    O
this    O
indication    O
.    O

D4A    O
is    O
an    O
inhibitor    O
of    O
CYP17A1    O
,    O
3β-hydroxysteroid    O
dehydrogenase/Δ5    O
-    O
4    O
isomerase    O
,    O
and    O
5α-reductase    O
,    O
and    O
has    O
also    O
been    O
found    O
to    O
act    O
as    O
a    O
competitive    O
antagonist    O
of    O
the    O
AR    O
reportedly    O
comparable    O
to    O
the    O
potent    O
antagonist    O
enzalutamide    B-Antineoplastic102722458
.    O

enzalutamide    B-Antineoplastic102722458
(    O
antiandrogen    O
)    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin    O
-    O
releasing    O
hormone    O
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogen    B-Antineoplastic102722458
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    O
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogens    O
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    B-Antineoplastic102722458
.    O

Medivation    O
,    O
in    O
collaboration    O
with    O
Astellas    O
,    O
is    O
currently    O
developing    O
enzalutamide    B-Antineoplastic102722458
for    O
multiple    O
stages    O
of    O
prostate    O
cancer    O
and    O
for    O
breast    O
cancer    O
.    O

The    O
retinoid    O
X    O
receptor    O
(    O
RXR    O
)    O
is    O
a    O
type    O
of    O
nuclear    O
receptor    O
that    O
is    O
activated    O
by    O
9-cis    B-Antineoplastic102722458
retinoic    I-Antineoplastic102722458
acid    I-Antineoplastic102722458
,    O
which    O
is    O
discussed    O
controversially    O
to    O
be    O
of    O
endogenous    O
relevance    O
,    O
and    O
9-cis-13,14-dihydro    O
-    O
retinoic    O
acid    O
,    O
which    O
is    O
likely    O
to    O
be    O
the    O
major    O
endogenous    O
mammalian    O
RXR    O
-    O
selective    O
agonist    O
.    O

Alitretinoin    B-Antineoplastic102722458
,    O
or    O
9-cis-retinoic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
,    O
is    O
a    O
form    O
of    O
vitamin    O
A.    O
It    O
is    O
also    O
used    O
in    O
medicine    O
as    O
an    O
antineoplastic    O
(    O
anti    O
-    O
cancer    O
)    O
agent    O
developed    O
by    O
Ligand    O
Pharmaceuticals    O
.    O

Localized    O
cutaneous    O
disease    O
can    O
be    O
treated    O
with    O
cryotherapy    O
,    O
intralesional    O
injections    O
of    O
vinblastine    O
,    O
alitretinoin    B-Antineoplastic102722458
gel    O
,    O
radiotherapy    O
,    O
topical    O
immunotherapy    O
(    O
Imiquimod    O
)    O
,    O
or    O
surgical    O
excision    O
.    O

Because    O
of    O
MDC1s    O
involvement    O
in    O
several    O
pathways    O
that    O
are    O
often    O
misappropriated    O
by    O
cancer    O
cells    O
including    O
the    O
cell    O
cycle    O
checkpoints    O
,    O
DDR    O
,    O
and    O
p53    O
tumor    O
suppression    O
,    O
cancer    O
treatments    O
that    O
target    O
"    O
MDC1    O
"    O
have    O
the    O
potential    O
to    O
be    O
potent    O
radiosensitizer    O
and    O
chemosensitizer    B-Antineoplastic102722458
.    O

Streptomyces    O
fragilis    O
"    O
produces    O
the    O
antibiotic    O
azaserine    B-Antineoplastic102722458
.    O

BI    B-Antineoplastic102722458
811283    I-Antineoplastic102722458
is    O
a    O
small    O
molecule    O
inhibitor    O
of    O
the    O
Aurora    O
B    O
kinase    O
protein    O
being    O
developed    O
by    O
Boehringer    O
Ingelheim    O
for    O
use    O
as    O
an    O
anti    O
-    O
cancer    O
agent    O
.    O

Chloroxymorphamine    B-Antineoplastic102722458

Suberoylanilide    B-Antineoplastic102722458
hydroxamic    I-Antineoplastic102722458
acid    I-Antineoplastic102722458
(    O
SAHA    O
)    O
(    O
a    O
HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
)    O
increases    O
expression    O
of    O
aquaporin-3    O
in    O
normal    O
skin    O
cells    O
(    O
keratinocytes    O
)    O
.    O

Studies    O
with    O
various    O
HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
and    O
neural    O
development    O
have    O
shown    O
increased    O
learning    O
and    O
memory    O
,    O
as    O
a    O
result    O
of    O
an    O
increased    O
acetylation    O
state    O
.    O

HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
enhance    O
LTP    O
,    O
this    O
is    O
dependent    O
on    O
rate    O
of    O
transcription    O

Histone    B-Antineoplastic102722458
deacetylase    I-Antineoplastic102722458
inhibitors    I-Antineoplastic102722458
(    O
HDAC    O
inhibitors    O
)    O
have    O
been    O
implicated    O
as    O
a    O
potential    O
treatment    O
for    O
cocaine    O
addicts    O
.    O

They    O
found    O
unexpected    O
patterns    O
of    O
brain    O
activation    O
in    O
awake    O
rats    O
that    O
were    O
exposed    O
to    O
sodium    O
butyrate    O
,    O
an    O
HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
(    O
or    O
HDACi    O
)    O
.    O

HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
have    O
been    O
implicated    O
as    O
a    O
potential    O
treatment    O
for    O
cocaine    O
addiction    O
.    O

Histone    B-Antineoplastic102722458
deacetylase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458

Belinostat    B-Antineoplastic102722458
(    O
trade    O
name    O
Beleodaq    B-Antineoplastic102722458
,    O
previously    O
known    O
as    O
PXD101    B-Antineoplastic102722458
)    O
is    O
a    O
histone    B-Antineoplastic102722458
deacetylase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
drug    O
developed    O
by    O
TopoTarget    O
for    O
the    O
treatment    O
of    O
hematological    O
malignancies    O
and    O
solid    O
tumors    O
.    O

Apicidin    O
is    O
a    O
fungal    O
metabolite    O
,    O
as    O
well    O
as    O
a    O
histone    B-Antineoplastic102722458
deacetylase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
.    O

In    O
2017    O
,    O
Xynomic    O
Pharmaceuticals    O
acquired    O
all    O
global    O
rights    O
to    O
abexinostat    B-Antineoplastic102722458
from    O
Pharmacyclics    O
.    O

2-Bromopropane    B-Antineoplastic102722458
(    O
isopropyl    O
bromide    O
)    O

Butyl    B-Antineoplastic102722458
iodide    I-Antineoplastic102722458
(    O
1-iodobutane    B-Antineoplastic102722458
)    O
is    O
an    O
organic    O
compound    O
which    O
is    O
an    O
iodo    O
derivative    O
of    O
butane    O
.    O

It    O
is    O
approved    O
for    O
use    O
in    O
form    O
of    O
the    O
combination    O
drug    O
trifluridine/tipiracil    B-Antineoplastic102722458
for    O
the    O
treatment    O
of    O
unresectable    O
advanced    O
or    O
recurrent    O
colorectal    O
cancer    O
.    O

Ibrutinib    B-Antineoplastic102722458
,    O
a    O
Bruton    O
's    O
tyrosine    O
kinase    O
(    O
BTK    O
)    O
inhibitor    O
,    O
is    O
used    O
to    O
treat    O
CLL    O
.    O

In    O
November    O
2013    O
,    O
ibrutinib    B-Antineoplastic102722458
was    O
approved    O
by    O
the    O
US    O
FDA    O
for    O
treating    O
MCL    O
.    O

Competition    O
is    O
expected    O
from    O
other    O
drugs    O
such    O
as    O
Imbruvica    O
(    O
ibrutinib    B-Antineoplastic102722458
)    O
and    O
Zydelig    O
(    O
idelalisib    B-Antineoplastic102722458
)    O
,    O
both    O
of    O
which    O
were    O
also    O
approved    O
in    O
2014    O
to    O
treat    O
CLL    O
(    O
chronic    O
lymphocytic    O
leukemia    O
)    O
.    O

However    O
,    O
when    O
rats    O
were    O
treated    O
with    O
the    O
DNMT    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
zebularine    O
or    O
5-aza-2′-deoxycytidine    O
immediately    O
after    O
fear    O
-    O
conditioning    O
,    O
they    O
demonstrated    O
reduced    O
learning    O
(    O
freezing    O
behavior    O
)    O
.    O

One    O
important    O
acylfulvene    O
,    O
6-hydroxymethylacylfulvene    O
(    O
irofulven    B-Antineoplastic102722458
)    O
,    O
has    O
been    O
evaluated    O
for    O
the    O
treatment    O
of    O
a    O
wide    O
assortment    O
of    O
cancers    O
and    O
tumors    O
.    O

Flavopiridol    O
(    O
alvocidib    B-Antineoplastic102722458
)    O
is    O
the    O
first    O
CDK    O
inhibitor    O
to    O
be    O
tested    O
in    O
clinical    O
trials    O
after    O
being    O
identified    O
in    O
an    O
anti    O
-    O
cancer    O
agent    O
screen    O
in    O
1992    O
.    O

In    O
this    O
case    O
,    O
more    O
aggressive    O
therapies    O
,    O
including    O
lenalidomide    O
,    O
flavopiridol    B-Antineoplastic102722458
,    O
and    O
bone    O
marrow    O
(    O
stem    O
cell    O
)    O
transplantation    O
,    O
are    O
considered    O
.    O

Cell-cycle    B-Antineoplastic102722458
nonspecific    I-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agents    I-Antineoplastic102722458
(    O
CCNS    B-Antineoplastic102722458
)    O
refer    O
to    O
a    O
class    O
of    O
pharmaceuticals    O
that    O
act    O
as    O
antitumor    O
agents    O
at    O
all    O
or    O
any    O
phases    O
of    O
the    O
cell    O
cycle    O
.    O

Some    O
VEGFR    O
antagonists    O
(    O
inhibitors    O
)    O
(    O
for    O
example    O
lenvatinib    O
,    O
motesanib    B-Antineoplastic102722458
)    O
are    O
under    O
investigation    O
for    O
treating    O
various    O
cancers    O
.    O

fosbretabulin    B-Antineoplastic102722458
(    O
USAN    O
,    O
INN    O
)    O

Streptomyces    O
cuspidosporus    O
"    O
produces    O
xylanase    O
,    O
sparsomycin    B-Antineoplastic102722458
and    O
tubercidin    O
.    O

The    O
eastern    O
rivers    O
,    O
Jora    O
,    O
Ula    O
,    O
Frya    O
,    O
Tromsa    O
and    O
Mesna    B-Antineoplastic102722458
are    O
shorter    O
and    O
drop    O
precipitously    O
from    O
the    O
heights    O
of    O
the    O
Rondane    O
.    O

Mesna    B-Antineoplastic102722458

Mesna    B-Antineoplastic102722458
,    O
sold    O
under    O
the    O
brand    O
name    O
Mesnex    B-Antineoplastic102722458
among    O
others    O
,    O
is    O
a    O
medication    O
used    O
in    O
those    O
taking    O
cyclophosphamide    O
or    O
ifosfamide    O
to    O
decrease    O
the    O
risk    O
of    O
bleeding    O
from    O
the    O
bladder    O
.    O

A    O
toxic    O
ether    O
lipid    O
analogue    O
miltefosine    B-Antineoplastic102722458
has    O
recently    O
been    O
introduced    O
as    O
an    O
oral    O
treatment    O
for    O
the    O
tropical    O
disease    O
leishmaniasis    O
,    O
which    O
is    O
caused    O
by    O
leishmania    O
,    O
a    O
protozoal    O
parasite    O
with    O
a    O
particularly    O
high    O
ether    O
lipid    O
content    O
in    O
its    O
membranes    O
.    O

Miltefosine    B-Antineoplastic102722458
,    O
sold    O
under    O
the    O
trade    O
name    O
Impavido    B-Antineoplastic102722458
among    O
others    O
,    O
is    O
a    O
medication    O
mainly    O
used    O
to    O
treat    O
leishmaniasis    O
and    O
free    O
-    O
living    O
amoeba    O
infections    O
such    O
as    O
"    O
Naegleria    O
fowleri    O
"    O
.    O

Miltefosine    B-Antineoplastic102722458
(    O
for    O
the    O
treatment    O
of    O
visceral    O
and    O
cutaneous    O
leishmaniasis    O
,    O
currently    O
undergoing    O
investigation    O
for    O
Chagas    O
disease    O
)    O

foretinib    B-Antineoplastic102722458
(    O
USAN    O
,    O
INN    O
)    O

The    O
brothers    O
were    O
taken    O
by    O
force    O
to    O
West    O
Virginia    O
,    O
to    O
await    O
the    O
fate    O
of    O
mortally    O
wounded    O
Ellison    O
Hatfield    O
and    O
when    O
Ellison    O
died    O
from    O
his    O
injuries    O
,    O
the    O
McCoy    O
brothers    O
were    O
killed    O
by    O
the    O
Hatfields    O
'    O
vigilante    O
justice    O
in    O
turn    O
:    O
being    O
tied    O
to    O
pawpaw    B-Antineoplastic102722458
bushes    O
,    O
where    O
each    O
was    O
shot    O
numerous    O
times    O
with    O
a    O
total    O
of    O
50    O
shots    O
fired    O
.    O

Plants    O
in    O
the    O
genus    O
"    O
Asimina    B-Antineoplastic102722458
"    O
,    O
commonly    O
referred    O
to    O
as    O
"    O
pawpaw    O
"    O

"    O
Asimina    B-Antineoplastic102722458
"    O
(    O
pawpaw    O
)    O
"    O

Winged    O
sumac    O
,    O
which    O
provides    O
red    O
fruit    O
for    O
small    O
warblers    O
and    O
other    O
wildlife    O
in    O
the    O
fall    O
,    O
pawpaws    O
(    O
"    O
Asimina    B-Antineoplastic102722458
"    O
)    O
,    O
Saw    O
palmettos    O
,    O
cocoplum    O
,    O
wax    O
myrtle    O
,    O
tarflower    O
(    O
"    O
Befaria    O
racemosa    O
"    O
)    O
as    O
well    O
as    O
the    O
endangered    O
quailberry    O
(    O
"    O
Crossopetalum    O
ilicifolium    O
"    O
)    O
.    O
Blueberry    O
and    O
rusty    O
lyonia    O
.    O

Model    O
of    O
the    O
inhibitor    O
olaparib    B-Antineoplastic102722458
(    O
dark    O
gray    O
)    O
occupying    O
the    O
NAD+-binding    O
site    O
of    O
PARP1    O
.    O

Olaparib    B-Antineoplastic102722458
,    O
a    O
PARP1    O
inhibitor    O
,    O
shrunk    O
or    O
stopped    O
the    O
growth    O
of    O
tumors    O
from    O
breast    O
,    O
ovarian    O
and    O
prostate    O
cancers    O
caused    O
by    O
mutations    O
in    O
the    O
BRCA1    O
or    O
BRCA2    O
genes    O
,    O
which    O
are    O
necessary    O
for    O
HR    O
.    O

Talazoparib    O
is    O
similar    O
to    O
the    O
first    O
in    O
class    O
PARP    O
inhibitor    O
,    O
olaparib    B-Antineoplastic102722458
.    O

Adozelesin    B-Antineoplastic102722458
is    O
an    O
experimental    O
antitumor    O
drug    O
of    O
the    O
duocarmycin    B-Antineoplastic102722458
class    O
.    O

Acridine    B-Antineoplastic102722458
carboxamide    I-Antineoplastic102722458
is    O
an    O
chemotherapy    O
agent    O
that    O
is    O
being    O
studied    O
in    O
the    O
treatment    O
of    O
cancer    O
.    O

Sonidegib    B-Antineoplastic102722458
was    O
approved    O
in    O
2015    O
for    O
the    O
same    O
indication    O
.    O

File    O
:    O
Salinosporamide    O
Salinosporamide    B-Antineoplastic102722458
A    I-Antineoplastic102722458

the    O
Also    O
called    O
RPI.4610    B-Antineoplastic102722458

He    O
traveled    O
to    O
the    O
Stanford    O
University    O
Medical    O
Center    O
for    O
chemotherapy    O
and    O
treatment    O
with    O
the    O
experimental    O
drug    O
,    O
vatalanib    B-Antineoplastic102722458
,    O
which    O
doctors    O
hoped    O
would    O
cut    O
off    O
the    O
blood    O
supply    O
to    O
the    O
tumor    O
.    O

Chemoimmunotherapy    B-Antineoplastic102722458
is    O
chemotherapy    O
combined    O
with    O
immunotherapy    O
.    O

Frequently    O
used    O
topical    O
retinoids    O
include    O
adapalene    O
,    O
isotretinoin    O
,    O
retinol    O
,    O
tazarotene    O
,    O
and    O
tretinoin    B-Antineoplastic102722458
.    O

Subsequently    O
,    O
in    O
the    O
1970s    O
tretinoin    B-Antineoplastic102722458
(    O
original    O
trade    O
name    O
Retin    O
A    O
)    O
was    O
found    O
to    O
be    O
an    O
effective    O
treatment    O
.    O

To    O
treat    O
these    O
conditions    O
,    O
Jackson    O
used    O
Solaquin    O
,    O
Tretinoin    B-Antineoplastic102722458
,    O
and    O
Benoquin    O
.    O

Tretinoin    B-Antineoplastic102722458
,    O
an    O
acid    O
that    O
increases    O
skin    O
cell    O
(    O
keratinocyte    O
)    O
turnover    O
.    O

TIsotretinoin    O
,    O
high    O
doses    O
of    O
vitamin    O
A    O
and    O
tretinoin    B-Antineoplastic102722458
cream    O
can    O
be    O
utilized    O
.    O

Fourteen    O
patients    O
with    O
hypopigmented    O
in    O
their    O
scarreed    O
tissues    O
were    O
treated    O
with    O
the    O
FP    O
receptor    O
agonist    O
,    O
bimatoprost    O
,    O
applied    O
topically    O
plus    O
laser    O
therapy    O
and    O
topical    O
tretinoin    B-Antineoplastic102722458
or    O
pimecrolimus    O
.    O

In    O
combination    O
with    O
all-trans    B-Antineoplastic102722458
retinoic    I-Antineoplastic102722458
acid    I-Antineoplastic102722458
,    O
it    O
is    O
FDA    O
-    O
approved    O
as    O
first    O
-    O
line    O
treatment    O
for    O
promyelocytic    O
leukemia    O
.    O

Tretinoin    B-Antineoplastic102722458
(    O
Tradename    O
:    O
Retin    O
-    O
A    O
)    O

Topical    O
creams    O
and    O
lotions    O
are    O
currently    O
the    O
most    O
commonly    O
used    O
treatment    O
for    O
keratosis    O
pilaris    O
,    O
specifically    O
those    O
consisting    O
of    O
moisturizing    O
or    O
keratolytic    O
treatments    O
,    O
including    O
urea    O
,    O
lactic    O
acid    O
,    O
glycolic    O
acid    O
,    O
salicylic    O
acid    O
,    O
vitamin    O
D    O
,    O
or    O
topical    O
retinoids    O
such    O
as    O
tretinoin    B-Antineoplastic102722458
.    O

,    O
M.D.    O
,    O
(    O
February    O
25    O
,    O
1940    O
–    O
July    O
4    O
,    O
2013    O
)    O
was    O
an    O
American    O
dermatologist    O
and    O
medical    O
researcher    O
who    O
co    O
-    O
invented    O
Retin-A    B-Antineoplastic102722458
,    O
a    O
popular    O
acne    O
medication    O
,    O
in    O
1969    O
.    O

Fulton    O
co    O
-    O
developed    O
tretinoin    B-Antineoplastic102722458
,    O
known    O
by    O
the    O
brand    O
name    O
as    O
Retin-A    B-Antineoplastic102722458
,    O
with    O
Dr.    O
Albert    O
Kligman    O
.    O

8-Azaguanine    B-Antineoplastic102722458
is    O
a    O
purine    O
analog    O
with    O
the    O
chemical    O
formula    O
C4H4N6O.    O
It    O
has    O
been    O
widely    O
studied    O
for    O
its    O
biological    O
activity    O
.    O

Plomestane    B-Antineoplastic102722458
(    O
INN    O
,    O
USAN    O
;    O
former    O
developmental    O
code    O
name    O
MDL-18,962    B-Antineoplastic102722458
;    O
also    O
known    O
as    O
propargylestrenedione    B-Antineoplastic102722458
,    O
PED    B-Antineoplastic102722458
,    O
and    O
10-propargylestr-4-ene-3,17-dione    B-Antineoplastic102722458
)    O
is    O
a    O
steroidal    O
,    O
irreversible    O
aromatase    O
inhibitor    O
which    O
was    O
under    O
development    O
by    O
Marion    O
Merrell    O
Dow    O
/    O
Hoechst    O
Marion    O
Russell    O
(    O
now    O
Hoechst    O
AG    O
)    O
as    O
an    O
antineoplastic    O
agent    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
.    O

Pegaspargase    B-Antineoplastic102722458
(    O
Oncaspar    O
)    O
–    O
PEGylated    O
L    O
-    O
asparaginase    O
for    O
the    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
in    O
patients    O
who    O
are    O
hypersensitive    O
to    O
the    O
native    O
unmodified    O
form    O
of    O
L    O
-    O
asparaginase    O
(    O
Enzon    O
,    O
1994    O
)    O
.    O

It    O
is    O
an    O
analogue    O
of    O
the    O
chemotherapy    O
drug    O
lonidamine    B-Antineoplastic102722458
,    O
an    O
indazole    O
-    O
carboxylic    O
acid    O
,    O
and    O
further    O
studies    O
continue    O
to    O
be    O
conducted    O
into    O
this    O
family    O
of    O
drugs    O
as    O
possible    O
contraceptives    O
.    O

A    O
study    O
in    O
2013    O
indicated    O
that    O
Adjudin    O
,    O
similar    O
to    O
its    O
analogue    O
lonidamine    B-Antineoplastic102722458
,    O
has    O
properties    O
that    O
inhibit    O
cancer    O
growth    O
by    O
targeting    O
mitochondria    O
and    O
blocking    O
energy    O
metabolism    O
in    O
certain    O
kinds    O
of    O
tumor    O
cells    O
in    O
mice    O
,    O
indicating    O
that    O
it    O
has    O
potential    O
as    O
a    O
drug    O
for    O
cancer    O
therapy    O
.    O

The    O
results    O
of    O
various    O
studies    O
regarding    O
the    O
use    O
of    O
phytoestrogens    O
in    O
treating    O
breast    O
cancer    O
have    O
been    O
somewhat    O
contradictory    O
and    O
ambiguous    O
,    O
and    O
as    O
a    O
result    O
,    O
researchers    O
can    O
not    O
clearly    O
define    O
phytoestrogens    O
like    O
coumestrol    O
as    O
being    O
chemoprotective    B-Antineoplastic102722458
agent    I-Antineoplastic102722458
or    O
potentially    O
having    O
negative    O
effects    O
,    O
such    O
as    O
inducing    O
further    O
growth    O
of    O
existing    O
breast    O
cancer    O
tumors    O
by    O
activating    O
ERα    O
receptors    O
.    O

Levoleucovorin    O
is    O
the    O
enantiomerically    O
active    O
form    O
of    O
Folinic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
.    O

An    O
individual    O
with    O
the    O
gene    O
variant    O
or    O
SNP    O
(    O
single    O
nucleotide    O
polymorphism    O
)    O
may    O
need    O
increased    O
intake    O
of    O
and    O
Folinic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
to    O
override    O
the    O
effect    O
of    O
a    O
variant    O
SNP    O
.    O

During    O
this    O
period    O
Eisenberg    O
published    O
studies    O
on    O
Colorectal    O
cancer    O
,    O
and    O
the    O
use    O
of    O
a    O
new    O
chemotherapy    O
technique    O
for    O
colon    O
cancer    O
patients    O
using    O
Irinotecan    O
,    O
5-Fluorouracil    O
,    O
and    O
Leucovorin    B-Antineoplastic102722458
.    O

She    O
has    O
also    O
found    O
that    O
administering    O
these    O
compounds    O
as    O
supplements    O
,    O
as    O
well    O
as    O
methylcobalamin    O
and    O
folinic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
,    O
to    O
autistic    O
children    O
can    O
significantly    O
restore    O
their    O
levels    O
of    O
glutathione    O
and    O
cysteine    O
and    O
may    O
therefore    O
be    O
useful    O
in    O
the    O
treatment    O
of    O
autism    O
.    O

Folinic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
,    O
also    O
known    O
as    O
leucovorin    B-Antineoplastic102722458
,    O
is    O
a    O
medication    O
used    O
to    O
decrease    O
the    O
toxic    O
effects    O
of    O
methotrexate    O
and    O
pyrimethamine    O
.    O

However    O
,    O
due    O
to    O
a    O
low    O
level    O
of    O
5-FU    O
found    O
in    O
many    O
patients    O
,    O
it    O
has    O
been    O
discovered    O
that    O
in    O
combination    O
with    O
leucovorin    B-Antineoplastic102722458
(    O
LV    O
)    O
,    O
5-FU    O
has    O
greater    O
success    O
in    O
down    O
regulating    O
tumor    O
progression    O
mechanisms    O
and    O
increasing    O
immune    O
system    O
activity    O
.    O

DHFR    O
mutations    O
cause    O
a    O
rare    O
autosomal    O
recessive    O
inborn    O
error    O
of    O
folate    O
metabolism    O
that    O
results    O
in    O
megaloblastic    O
anemia    O
,    O
pancytopenia    O
and    O
severe    O
cerebral    O
folate    O
deficiency    O
which    O
can    O
be    O
corrected    O
by    O
folinic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
supplementation    O
.    O

Treatment    O
of    O
THB    O
deficiencies    O
consists    O
of    O
THB    O
supplementation    O
(    O
2–20    O
mg    O
/    O
kg    O
per    O
day    O
)    O
or    O
diet    O
to    O
control    O
blood    O
phenylalanine    O
concentration    O
and    O
replacement    O
therapy    O
with    O
neurotransmitters    O
precursors    O
(    O
L    O
-    O
DOPA    O
and    O
5-HTP    O
)    O
and    O
supplements    O
of    O
folinic    B-Antineoplastic102722458
acid    I-Antineoplastic102722458
in    O
DHPR    O
deficiency    O
.    O

Lurtotecan    B-Antineoplastic102722458
is    O
a    O
semi    O
-    O
synthetic    O
analog    O
of    O
camptothecin    O
with    O
antineoplastic    O
activity    O
.    O

Brostallicin    B-Antineoplastic102722458
is    O
a    O
chemical    O
compound    O
being    O
studied    O
in    O
the    O
treatment    O
of    O
cancer    O
.    O

Examples    O
include    O
SPPARMs    O
of    O
the    O
PPARγ    O
,    O
BADGE    O
,    O
EPI-001    B-Antineoplastic102722458
,    O
INT-131    O
,    O
MK-0533    O
,    O
and    O
S26948    O
.    O

It    O
was    O
a    O
successor    O
of    O
EPI-001    B-Antineoplastic102722458
and    O
targets    O
the    O
N    O
-    O
terminal    O
domain    O
(    O
NTD    O
)    O
of    O
the    O
androgen    O
receptor    O
(    O
AR    O
)    O
.    O

Therefore    O
,    O
alternative    O
regimens    O
were    O
tested    O
in    O
an    O
attempt    O
to    O
avoid    O
alkylating    B-Antineoplastic102722458
agent    I-Antineoplastic102722458
(    O
such    O
as    O
mechlorethamine    O
)    O
,    O
which    O
were    O
thought    O
to    O
be    O
responsible    O
for    O
many    O
of    O
the    O
long    O
-    O
term    O
side    O
effects    O
of    O
MOPP    O
.    O

Chemotherapies    O
with    O
high    O
risk    O
include    O
procarbazine    O
and    O
alkylating    B-Antineoplastic102722458
drug    I-Antineoplastic102722458
such    O
as    O
cyclophosphamide    O
,    O
ifosfamide    O
,    O
busulfan    O
,    O
melphalan    O
,    O
chlorambucil    O
and    O
chlormethine    O
.    O

They    O
act    O
as    O
alkylating    O
agents    O
,    O
some    O
of    O
them    O
are    O
used    O
as    O
alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
in    O
the    O
treatment    O
of    O
cancer    O
,    O
e.g.    O
Busulfan    O
.    O

Alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
and    O
anthracyclins    O
are    O
two    O
examples    O
.    O

An    O
alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
is    O
an    O
alkylating    O
agent    O
used    O
in    O
cancer    O
treatment    O
that    O
attaches    O
an    O
alkyl    O
group    O
(    O
CnH2n+1    O
)    O
to    O
DNA    O
.    O

It    O
was    O
approved    O
by    O
the    O
US    O
Food    O
and    O
Drug    O
Administration    O
for    O
CLL    O
patients    O
who    O
have    O
been    O
treated    O
with    O
alkylating    B-Antineoplastic102722458
agent    I-Antineoplastic102722458
and    O
who    O
have    O
failed    O
fludarabine    O
therapy    O
.    O

ICI-85966    O
(    O
former    O
tentative    O
brand    O
name    O
Stilbostat    O
)    O
,    O
also    O
known    O
as    O
diethylstilbestrol    O
(    O
DES    O
)    O
bis(di(2-chloroethyl)carbamate    O
)    O
,    O
is    O
a    O
synthetic    O
,    O
nonsteroidal    O
estrogen    O
and    O
alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
of    O
the    O
stilbestrol    O
group    O
and    O
a    O
cytostatic    O
nitrogen    O
mustard    O
ester    O
of    O
diethylstilbestrol    O
(    O
DES    O
)    O
that    O
was    O
developed    O
for    O
the    O
treatment    O
of    O
breast    O
cancer    O
and    O
prostate    O
cancer    O
but    O
was    O
never    O
marketed    O
.    O

Estromustine    O
(    O
developmental    O
code    O
name    O
Leo    O
271    O
f    O
)    O
,    O
also    O
known    O
as    O
estrone    O
17β-3-N    O
-    O
bis(2-chloroethyl)carbamate    O
or    O
estrone    O
-    O
cytostatic    O
complex    O
,    O
is    O
a    O
major    O
active    O
metabolite    O
of    O
the    O
cystotatic    O
estrogen    O
and    O
nitrogen    O
mustard    O
alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
estramustine    O
phosphate    O
,    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
.    O

Phenestrol    O
(    O
developmental    O
code    O
name    O
NSC-183736    O
)    O
,    O
or    O
fenestrol    O
,    O
also    O
known    O
as    O
hexestrol    O
bis[4-[bis(2-chloroethyl)amino]phenylacetate    O
,    O
is    O
a    O
synthetic    O
,    O
nonsteroidal    O
estrogen    O
and    O
alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
(    O
i.e.    O
,    O
chemotherapy    O
drug    O
)    O
and    O
a    O
chlorphenacyl    O
nitrogen    O
mustard    O
ester    O
of    O
hexestrol    O
that    O
was    O
developed    O
in    O
the    O
early    O
1960s    O
for    O
the    O
treatment    O
of    O
hormone    O
-    O
dependent    O
tumors    O
but    O
was    O
never    O
marketed    O
.    O

Estradiol    O
mustard    O
(    O
developmental    O
code    O
name    O
NSC-112259    O
)    O
,    O
also    O
known    O
as    O
chlorphenacyl    O
estradiol    O
diester    O
,    O
as    O
well    O
as    O
estradiol    O
3,17β-bis(4-(bis(2-chloroethyl)amino)phenyl)acetate    O
,    O
is    O
a    O
synthetic    O
,    O
steroidal    O
estrogen    O
and    O
alkylating    B-Antineoplastic102722458
antineoplastic    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
and    O
a    O
chlorphenacyl    O
nitrogen    O
mustard    O
-    O
coupled    O
estrogen    O
ester    O
that    O
was    O
never    O
marketed    O
.    O

efaproxiral    B-Antineoplastic102722458
(    O
USAN    O
)    O

Based    O
on    O
its    O
known    O
structures    O
while    O
bound    O
to    O
two    O
steroidal    O
inhibitors    O
,    O
abiraterone    O
and    O
galeterone    B-Antineoplastic102722458
,    O
CYP17A1    O
possesses    O
the    O
canonical    O
cytochrome    O
P450    O
fold    O
present    O
in    O
other    O
complex    O
P450    O
enzymes    O
that    O
participate    O
in    O
steroidogenesis    O
or    O
cholesterol    O
metabolism    O
,    O
though    O
it    O
orients    O
the    O
steroid    O
ligands    O
toward    O
the    O
F    O
and    O
G    O
helices    O
,    O
perpendicular    O
to    O
the    O
heme    O
group    O
,    O
rather    O
than    O
the    O
β1    O
sheet    O
.    O

Since    O
2014    O
,    O
galeterone    B-Antineoplastic102722458
has    O
been    O
in    O
phase    O
III    O
clinical    O
trials    O
for    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
.    O

:    O
H01CB04    O
Vapreotide    B-Antineoplastic102722458

Chemically    O
bonded    O
iron    O
-    O
oxide    O
nanoparticles    O
were    O
coated    O
with    O
about    O
20    O
molecules    O
of    O
chlorotoxin    B-Antineoplastic102722458
and    O
targeted    O
to    O
brain    O
-    O
metastatic    O
cancer    O
cells    O
.    O

Autoclave-resistant    B-Antineoplastic102722458
factor    I-Antineoplastic102722458
is    O
a    O
substance    O
found    O
in    O
soybeans    O
that    O
may    O
slow    O
down    O
or    O
stop    O
the    O
spread    O
of    O
cancer    O
.    O

Bis(chloromethyl)    B-Antineoplastic102722458
ether    I-Antineoplastic102722458
is    O
an    O
organic    O
compound    O
with    O
the    O
chemical    O
formula    O
(    O
CH2Cl)2O.    O
It    O
is    O
a    O
colourless    O
liquid    O
with    O
an    O
unpleasant    O
suffocating    O
odour    O
and    O
it    O
is    O
one    O
of    O
the    O
chloroalkyl    O
ethers    O
.    O

Tivantinib    B-Antineoplastic102722458
(    O
ARQ197    B-Antineoplastic102722458
;    O
by    O
Arqule    O
,    O
Inc.    O
)    O
is    O
an    O
experimental    O
small    O
molecule    O
anti    O
-    O
cancer    O
drug    O
.    O

Other    O
agents    O
which    O
have    O
been    O
shown    O
to    O
reverse    O
chloroquine    O
resistance    O
in    O
malaria    O
are    O
chlorpheniramine    O
,    O
gefitinib    O
,    O
imatinib    O
,    O
tariquidar    B-Antineoplastic102722458
and    O
zosuquidar    B-Antineoplastic102722458
.    O

3,3′-Diindolylmethane    B-Antineoplastic102722458
(    O
DIM    B-Antineoplastic102722458
)    O
is    O
a    O
compound    O
derived    O
from    O
the    O
digestion    O
of    O
indole-3-carbinol    O
,    O
found    O
in    O
cruciferous    O
vegetables    O
such    O
as    O
broccoli    O
,    O
Brussels    O
sprouts    O
,    O
cabbage    O
and    O
kale    O
.    O

The    O
following    O
is    O
a    O
list    O
of    O
ALK    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
currently    O
in    O
clinical    O
trials    O
for    O
treatment    O
of    O
neuroblastoma    O
:    O

It    O
has    O
been    O
suggested    O
that    O
mesoblastic    O
nephroma    O
patients    O
with    O
lymph    O
node    O
involvement    O
or    O
recurrent    O
disease    O
might    O
benefit    O
by    O
adding    O
the    O
ALK    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
,    O
crizotinib    O
,    O
or    O
a    O
tyrosine    O
kinase    O
inhibitor    O
,    O
either    O
larotrectinib    O
or    O
entrectinib    O
,    O
to    O
surgical    O
,    O
radiation    O
,    O
and/or    O
chemotherapy    O
treatment    O
regimens    O
.    O

Thymidylate    B-Antineoplastic102722458
synthase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458

Other    O
targeted    O
agents    O
include    O
the    O
proteasome    O
inhibitor    O
bortezomib    O
,    O
mTOR    O
inhibitors    O
such    O
as    O
temsirolimus    B-Antineoplastic102722458
,    O
and    O
the    O
P110δ    O
inhibitor    O
GS-1101    O
.    O

In    O
mouse    O
studies    O
,    O
these    O
symptoms    O
can    O
be    O
avoided    O
through    O
the    O
use    O
of    O
alternate    O
dosing    O
regimens    O
or    O
analogs    O
such    O
as    O
everolimus    B-Antineoplastic102722458
or    O
temsirolimus    B-Antineoplastic102722458
.    O

Other    O
mTOR    O
inhibitors    O
,    O
such    O
as    O
temsirolimus    B-Antineoplastic102722458
(    O
CCI-779    O
)    O
or    O
everolimus    B-Antineoplastic102722458
(    O
RAD001    O
)    O
,    O
are    O
being    O
tested    O
for    O
use    O
in    O
cancers    O
such    O
as    O
glioblastoma    O
multiforme    O
and    O
mantle    O
cell    O
lymphoma    O
.    O

Example    O
drugs    O
include    O
Tirapazamine    B-Antineoplastic102722458
and    O
Evofosfamide    B-Antineoplastic102722458
.    O

A    O
maytansinoid    B-Antineoplastic102722458
is    O
a    O
chemical    O
derivative    O
of    O
maytansine    O
.    O

Bromobimane    B-Antineoplastic102722458
(    O
or    O
monobromobimane    B-Antineoplastic102722458
)    O
is    O
a    O
heterocyclic    O
compound    O
and    O
bimane    O
dye    O
that    O
is    O
used    O
as    O
a    O
reagent    O
in    O
biochemistry    O
.    O

Zoptarelin    B-Antineoplastic102722458
doxorubicin    I-Antineoplastic102722458
consists    O
of    O
doxorubicin    O
linked    O
to    O
a    O
small    O
peptide    O
agonist    O
to    O
the    O
luteinizing    O
hormone    O
-    O
releasing    O
hormone    O
(    O
LHRH    O
)    O
receptor    O
.    O

It    O
is    O
thought    O
that    O
this    O
action    O
may    O
possibly    O
be    O
responsible    O
for    O
much    O
of    O
the    O
antiinflammatory    O
,    O
antihyperplastic    O
,    O
chemopreventative    B-Antineoplastic102722458
,    O
antihyperlipidemic    O
,    O
antidiabetic    O
,    O
and    O
antiobesic    O
,    O
as    O
well    O
as    O
certain    O
immunomodulating    O
activities    O
of    O
DHEA    O
(    O
with    O
some    O
experimental    O
evidence    O
to    O
support    O
this    O
notion    O
available    O
)    O
.    O

It    O
is    O
used    O
as    O
an    O
anticancer    B-Antineoplastic102722458
drug    O
as    O
it    O
is    O
able    O
to    O
intercalate    O
into    O
DNA    O
at    O
the    O
cytosine    O
-    O
cytosine    O
sites    O
.    O

HU-331    O
is    O
a    O
quinone    O
anticarcinogenic    B-Antineoplastic102722458
drug    O
synthesized    O
from    O
cannabidiol    O
,    O
a    O
cannabinoid    O
in    O
the    O
"    O
Cannabis    O
sativa    O
"    O
plant    O
.    O

HU-331    O
inhibits    O
DNA    O
topoisomerase    O
II    O
even    O
at    O
nanomolar    O
concentrations    O
,    O
but    O
has    O
shown    O
a    O
negligible    O
effect    O
on    O
the    O
action    O
of    O
DNA    O
topoisomerase    O
I.    O
The    O
cannabinoid    O
quinone    O
HU-331    O
is    O
a    O
very    O
specific    O
inhibitor    O
of    O
topoisomerase    O
II    O
,    O
compared    O
with    O
most    O
known    O
anticancer    B-Antineoplastic102722458
quinones    O
.    O

Two    O
major    O
research    O
areas    O
of    O
Hosmane    O
include    O
blood    O
substitutes    O
based    O
on    O
hemoglobins    O
and    O
the    O
discovery    O
of    O
antiviral    O
and    O
anticancer    B-Antineoplastic102722458
compounds    O
based    O
on    O
ring    O
-    O
expanded    O
nucleoside    O
structures    O
.    O

Other    O
medical    O
properties    O
from    O
different    O
extracts    O
include    O
antimicrobial    O
,    O
anticarcirogenic    B-Antineoplastic102722458
,    O
antiinflammatory    O
and    O
antihypertensive    O
.    O

The    O
compound    O
has    O
shown    O
some    O
"    O
in    O
vitro    O
"    O
anticancer    B-Antineoplastic102722458
,    O
antiestrogenic    B-Antineoplastic102722458
,    O
immunomodulatory    O
,    O
and    O
anti    O
-    O
amoebic    O
activity    O
(    O
particularly    O
against    O
"    O
Entamoeba    O
histolytica    O
"    O
)    O
.    O

Pharmacological    O
activities    O
include    O
antiinflammatory    O
,    O
hepatoprotective    O
,    O
anticancer    B-Antineoplastic102722458
,    O
antidiabetic    O
,    O
antioxidant    O
,    O
antibacterial    O
,    O
antifungal    O
,    O
analgesic    O
,    O
anti    O
-    O
infertility    O
and    O
central    O
nervous    O
system    O
depressant    O
activity    O
.    O

This    O
compound    O
–    O
found    O
in    O
the    O
"    O
Euphorbia    O
"    O
genus    O
of    O
plants    O
–    O
is    O
of    O
great    O
interest    O
to    O
drug    O
developers    O
for    O
its    O
anticarcinogen    B-Antineoplastic102722458
properties    O
.    O

Resimmune    B-Antineoplastic102722458
,    O
or    O
A    O
-    O
dmDT390-bisFv(UCHT1    O
)    O
,    O
an    O
experimental    O
anti    O
-    O
T    O
cell    O
immunotoxin    O
in    O
clinical    O
trials    O
to    O
treat    O
cutaneous    O
T    O
-    O
cell    O
lymphoma    O
and    O
metastatic    O
melanoma    O
.    O

Veliparib    B-Antineoplastic102722458
(    O
ABT-888    O
)    O
for    O
metastatic    O
melanoma    O
.    O

Bcl-2    O
inhibitors    O
(    O
e.g.    O
obatoclax    B-Antineoplastic102722458
in    O
clinical    O
trials    O
,    O
navitoclax    O
,    O
and    O
gossypol    O
.    O

masoprocol    B-Antineoplastic102722458
(    O
INN    O
)    O

tilomisole    B-Antineoplastic102722458
(    O
INN    O
)    O

Polluted    O
air    O
(    O
1-bromobutane    B-Antineoplastic102722458
)    O
was    O
pumped    O
for    O
a    O
very    O
short    O
time    O
,    O
and    O
therefore    O
,    O
such    O
tests    O
do    O
not    O
reduce    O
the    O
service    O
life    O
considerably    O
.    O

In    O
1992    O
a    O
team    O
of    O
Johns    O
Hopkins    O
University    O
scientists    O
isolated    O
a    O
cancer    O
-    O
fighting    O
phytochemical    O
in    O
broccoli    O
called    O
glucoraphanin    O
,    O
which    O
is    O
the    O
glucosinolate    O
precursor    O
of    O
sulforaphane    B-Antineoplastic102722458
(    O
SGS    O
)    O
.    O

Glucoraphanin    O
is    O
the    O
precursor    O
to    O
sulforaphane    B-Antineoplastic102722458

Plants    O
producing    O
large    O
amounts    O
of    O
glucosinolates    O
are    O
under    O
basic    O
research    O
for    O
potential    O
actions    O
against    O
cancer    O
,    O
with    O
the    O
hydrolysis    O
product    O
of    O
the    O
glucoraphanin    O
(    O
the    O
primary    O
glucosinolate    O
in    O
broccoli    O
)    O
,    O
sulforaphane    B-Antineoplastic102722458
,    O
being    O
the    O
best    O
known    O
example    O
.    O

Indolocarbazole    B-Antineoplastic102722458

Owing    O
to    O
its    O
selectivity    O
for    O
the    O
,    O
unlike    O
such    O
as    O
and    O
megestrol    O
acetate    O
,    O
bicalutamide    O
does    O
not    O
bind    O
to    O
other    O
steroid    O
hormone    O
receptors    O
,    O
and    O
for    O
this    O
reason    O
,    O
has    O
no    O
additional    O
,    O
off    O
-    O
target    O
hormonal    O
activity    O
(    O
estrogenic    O
or    O
antiestrogen    B-Antineoplastic102722458
,    O
progestogenic    O
or    O
antiprogestogen    B-Antineoplastic102722458
,    O
glucocorticoid    O
or    O
antiglucocorticoid    O
,    O
or    O
mineralocorticoid    O
or    O
antimineralocorticoid    O
)    O
;    O
nor    O
does    O
it    O
inhibit    O
5α-reductase    O
.    O

By    O
inhibiting    O
3β-HSD    O
,    O
epostane    O
blocks    O
the    O
biosynthesis    O
of    O
progesterone    O
from    O
pregnenolone    O
(    O
and    O
also    O
the    O
conversion    O
of    O
dehydroepiandrosterone    O
to    O
androstenedione    O
)    O
,    O
thereby    O
functioning    O
as    O
an    O
antiprogestogen    B-Antineoplastic102722458
and    O
terminating    O
pregnancy    O
.    O

It    O
is    O
an    O
antagonist    O
of    O
the    O
androgen    O
receptor    O
(    O
Ki    O
=    O
2.2    O
μM    O
)    O
,    O
and    O
with    O
the    O
exception    O
of    O
antiprogestogen    B-Antineoplastic102722458
activity    O
in    O
rat    O
and    O
rabbit    O
models    O
,    O
is    O
devoid    O
of    O
other    O
hormonal    O
activities    O
.    O

Valproic    O
acid    O
has    O
been    O
found    O
to    O
be    O
an    O
antagonist    O
of    O
the    O
androgen    O
and    O
progesterone    O
receptors    O
,    O
and    O
hence    O
as    O
a    O
nonsteroidal    O
antiandrogen    O
and    O
antiprogestogen    B-Antineoplastic102722458
,    O
at    O
concentrations    O
much    O
lower    O
than    O
therapeutic    O
serum    O
levels    O
.    O

Pharmalogical    O
drugs    O
can    O
also    O
be    O
given    O
accompanying    O
a    O
transsphenoidal    O
surgery    O
including    O
the    O
following    O
:    O
pasireotide    O
,    O
temozolomide    B-Antineoplastic102722458
and    O
octreotide    O
.    O

Although    O
temozolomide    B-Antineoplastic102722458
is    O
effective    O
for    O
treating    O
recurrent    O
anaplastic    O
astrocytoma    O
,    O
its    O
role    O
as    O
an    O
adjuvant    O
to    O
radiation    O
therapy    O
has    O
not    O
been    O
fully    O
tested    O
.    O

Some    O
sources    O
explicitly    O
exclude    O
the    O
triazenes    O
(    O
dacarbazine    O
,    O
mitozolomide    B-Antineoplastic102722458
,    O
temozolomide    B-Antineoplastic102722458
)    O
from    O
the    O
nonclassical    O
category    O
.    O

However    O
,    O
other    O
sources    O
list    O
dacarbazine    O
as    O
nonclassical    O
,    O
and    O
some    O
include    O
temozolomide    B-Antineoplastic102722458
.    O

Targeted    B-Antineoplastic102722458
molecular    I-Antineoplastic102722458
therapy    I-Antineoplastic102722458
for    O
neuroblastoma    O
involves    O
treatment    O
aimed    O
at    O
molecular    O
targets    O
that    O
have    O
a    O
unique    O
expression    O
in    O
this    O
form    O
of    O
cancer    O
.    O

Targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
attacks    O
cancer    O
cells    O
at    O
a    O
specific    O
target    O
,    O
with    O
the    O
aim    O
of    O
not    O
harming    O
normal    O
cells    O
.    O

More    O
specifically    O
,    O
they    O
are    O
used    O
as    O
a    O
vehicle    O
to    O
administer    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
,    O
in    O
the    O
form    O
of    O
recombinant    O
DNA    O
or    O
protein    O
.    O

For    O
example    O
,    O
It    O
has    O
been    O
suggested    O
that    O
inhibition    O
of    O
FADD    O
might    O
work    O
as    O
a    O
potential    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
for    O
drug    O
-    O
resistant    O
ovarian    O
cancer    O
.    O

Much    O
research    O
has    O
also    O
been    O
conducted    O
on    O
everolimus    O
and    O
other    O
mTOR    O
inhibitors    O
as    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
for    O
use    O
in    O
a    O
number    O
of    O
cancers    O
.    O

From    O
the    O
late    O
1990s    O
onwards    O
,    O
Goldman    O
was    O
instrumental    O
in    O
promoting    O
the    O
use    O
of    O
the    O
anti    O
-    O
cancer    O
drug    O
imatinib    O
,    O
working    O
to    O
refine    O
and    O
expand    O
its    O
clinical    O
usage    O
as    O
a    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
.    O

Oncology    O
Treatment    O
Center    O
provides    O
chemotherapy    O
,    O
radiation    O
therapy    O
,    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
,    O
and    O
other    O
forms    O
of    O
treatments    O
/    O
therapies    O
such    O
as    O
Stereotactic    O
Radiosurgery    O
(    O
SRS    O
)    O
,    O
Intensity    O
-    O
Modulated    O
Radiation    O
Therapy    O
(    O
IMRT    O
)    O
,    O
Image    O
-    O
Guided    O
Radiation    O
Therapy    O
(    O
IGRT    O
)    O
,    O
Volumetric    O
-    O
Modulated    O
Arc    O
Therapy    O
(    O
VMAT    O
)    O
,    O
Gamma    O
Knife    O
for    O
various    O
cancers    O
including    O
breast    O
cancer    O
,    O
lymphoma    O
,    O
and    O
esophagus    O
cancer    O
.    O

Targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458

Treatment    O
options    O
may    O
include    O
surgery    O
,    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
,    O
and    O
radiation    O
therapy    O
.    O

Because    O
most    O
systemic    O
drugs    O
have    O
no    O
efficacy    O
in    O
the    O
treatment    O
of    O
HCC    O
,    O
research    O
into    O
the    O
molecular    O
pathways    O
involved    O
in    O
the    O
production    O
of    O
liver    O
cancer    O
produced    O
sorafenib    O
,    O
a    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
drug    O
that    O
prevents    O
cell    O
proliferation    O
and    O
blood    O
cell    O
growth    O
.    O

Antibody-drug    B-Antineoplastic102722458
conjugates    I-Antineoplastic102722458
or    O
ADCs    B-Antineoplastic102722458
are    O
an    O
important    O
class    O
of    O
highly    O
potent    O
biopharmaceutical    O
drugs    O
designed    O
as    O
a    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
for    O
the    O
treatment    O
of    O
people    O
with    O
cancer    O
.    O

CD33    O
is    O
the    O
target    O
of    O
gemtuzumab    O
ozogamicin    O
(    O
trade    O
name    O
:    O
Mylotarg®    O
;    O
Pfizer    O
/    O
Wyeth    O
-    O
Ayerst    O
Laboratories    O
)    O
,    O
an    O
Antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
for    O
the    O
treatment    O
of    O
patients    O
with    O
acute    O
myeloid    O
leukemia    O
.    O

CD33    O
is    O
also    O
the    O
target    O
in    O
Vadastuximab    O
talirine    O
(    O
SGN    O
-    O
CD33A    O
)    O
,    O
a    O
novel    O
antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
being    O
developed    O
by    O
Seattle    O
Genetics    O
,    O
utilizing    O
this    O
company    O
's    O
newest    O
ADC    O
technology    O
.    O

Antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
using    O
calicheamicins    O
as    O
cytotoxic    O
agents    O
:    O

For    O
instance    O
,    O
emerging    O
promising    O
targeted    O
drug    O
therapies    O
,    O
antibody-drug    B-Antineoplastic102722458
conjugates    I-Antineoplastic102722458
,    O
are    O
constituted    O
of    O
three    O
main    O
components    O
:    O
a    O
monoclonal    O
antibody    O
,    O
a    O
cytotoxic    O
drug    O
,    O
and    O
a    O
linker    O
molecule    O
often    O
containing    O
a    O
maleimide    O
group    O
,    O
which    O
binds    O
the    O
drug    O
and    O
the    O
antibody    O
.    O

Vadastuximab    O
talirine    O
or    O
SGN    O
-    O
CD33A    O
is    O
an    O
antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
or    O
ADC    O
directed    O
to    O
CD33    O
(    O
SIGLEC-3    O
)    O
,    O
which    O
is    O
a    O
transmembrane    O
receptor    O
expressed    O
on    O
cells    O
of    O
myeloid    O
lineage    O
.    O

Antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
,    O
most    O
,    O
if    O
not    O
all    O
,    O
are    O
immunotoxins    O
but    O
use    O
whole    O
antibodies    O
and    O
non    O
-    O
protein    O
drugs    O

Antibody-drug    B-Antineoplastic102722458
conjugates    I-Antineoplastic102722458
or    O
ADCs    B-Antineoplastic102722458
are    O
an    O
important    O
class    O
of    O
highly    O
potent    O
biopharmaceutical    O
drugs    O
designed    O
as    O
a    O
targeted    B-Antineoplastic102722458
therapy    I-Antineoplastic102722458
for    O
the    O
treatment    O
of    O
people    O
with    O
cancer    O
.    O

Some    O
are    O
being    O
investigated    O
as    O
the    O
cytotoxic    O
component    O
of    O
antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
.    O

The    O
preclinical    O
agent    O
,    O
KTN0182A    O
,    O
is    O
an    O
anti    O
-    O
KIT    O
,    O
Pyrrolobenzodiazepine    O
(    O
PBD)-containing    O
antibody-drug    B-Antineoplastic102722458
conjugate    I-Antineoplastic102722458
which    O
shows    O
anti    O
-    O
tumor    O
activity    O
"    O
in    O
vitro    O
"    O
and    O
"    O
in    O
vivo    O
"    O
against    O
a    O
range    O
of    O
tumor    O
types    O
.    O

Phosphoinositide    B-Antineoplastic102722458
3-kinase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458

PI3K    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
(    O
e.g.    O
perifosine    O
in    O
a    O
phase    O
III    O
trial    O
)    O

On    O
September    O
3    O
,    O
2014    O
,    O
AbbVie    O
and    O
Infinity    O
Pharmaceuticals    O
announced    O
that    O
they    O
had    O
entered    O
into    O
a    O
global    O
collaboration    O
to    O
develop    O
and    O
commercialize    O
duvelisib    B-Antineoplastic102722458
,    O
Infinity    O
's    O
PI3    O
K    O
inhibitor    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
cancer    O
.    O

Canertinib    B-Antineoplastic102722458

Polymer-drug    B-Antineoplastic102722458
conjugates    I-Antineoplastic102722458

Example    O
drugs    O
include    O
Tirapazamine    B-Antineoplastic102722458
and    O
Evofosfamide    B-Antineoplastic102722458
.    O

Amonafide    B-Antineoplastic102722458

NK012    B-Antineoplastic102722458
is    O
a    O
'    O
nanodevice    O
'    O
formulation    O
of    O
SN-38    O
(    O
an    O
irinotecan    O
metabolite    O
)    O
.    O

Bropirimine    B-Antineoplastic102722458
is    O
an    O
experimental    O
drug    O
with    O
anti    O
-    O
cancer    O
and    O
antiviral    O
properties    O
.    O

Apatinib    B-Antineoplastic102722458
is    O
a    O
selective    O
VEGF    O
Receptor    O
2    O
inhibitor    O
which    O
has    O
shown    O
encouraging    O
anti    O
-    O
tumor    O
activity    O
in    O
a    O
broad    O
range    O
of    O
malignancies    O
in    O
clinical    O
trials    O
.    O

Topoisomerase    O
II    O
inhibitors    O
:    O
etoposide    O
(    O
VP-16    O
)    O
,    O
teniposide    O
,    O
doxorubicin    O
,    O
daunorubicin    O
,    O
mitoxantrone    O
,    O
amsacrine    B-Antineoplastic102722458
,    O
ellipticines    O
,    O
aurintricarboxylic    O
acid    O
,    O
and    O
HU-331    O
,    O
a    O
quinolone    O
synthesized    O
from    O
cannabidiol    O
.    O

"    O
eukaryotic    O
"    O
type    O
II    O
topoisomerase    O
inhibitors    O
(    O
topo    O
II    O
)    O
:    O
amsacrine    B-Antineoplastic102722458
,    O
etoposide    O
,    O
etoposide    O
phosphate    O
,    O
teniposide    O
and    O
doxorubicin    O
.    O

Iniparib    B-Antineoplastic102722458
(    O
INN    O
,    O
previously    O
known    O
as    O
BSI    B-Antineoplastic102722458
201    I-Antineoplastic102722458
)    O
was    O
a    O
drug    O
candidate    O
for    O
cancer    O
treatment    O
.    O

Laniquidar    B-Antineoplastic102722458
(    O
INN    O
)    O
is    O
a    O
P    O
-    O
glycoprotein    O
inhibitor    O
undergoing    O
clinical    O
studies    O
for    O
acute    O
myeloid    O
leukemia    O
(    O
AML    O
)    O
and    O
myelodysplastic    O
syndrome    O
(    O
MDS    O
)    O
.    O

Examples    O
include    O
racecadotril    O
,    O
ubenimex    B-Antineoplastic102722458
(    O
bestatin    O
)    O
,    O
RB-101    O
,    O
and    O
D    O
-    O
phenylalanine    O
,    O
as    O
well    O
as    O
the    O
endogenous    O
opioid    O
peptides    O
opiorphin    O
and    O
spinorphin    O
.    O

The    O
advantages    O
of    O
genetic    O
adjuvants    O
are    O
their    O
low    O
cost    O
and    O
simple    O
administration    O
,    O
as    O
well    O
as    O
avoidance    O
of    O
unstable    O
recombinant    O
cytokines    O
and    O
potentially    O
toxic    O
,    O
“    O
conventional    O
”    O
adjuvants    O
(    O
such    O
as    O
alum    O
,    O
calcium    O
phosphate    O
,    O
monophosphoryl    O
lipid    O
A    O
,    O
cholera    O
toxin    O
,    O
cationic    O
and    O
mannan    O
-    O
coated    O
liposomes    O
,    O
QS21    O
,    O
carboxymethyl    O
cellulose    O
and    O
ubenimix    B-Antineoplastic102722458
)    O
.    O

At    O
least    O
one    O
of    O
their    O
conjugates    O
,    O
IT-101    B-Antineoplastic102722458
,    O
has    O
been    O
investigated    O
in    O
a    O
clinical    O
trial    O
at    O
City    O
of    O
Hope    O
National    O
Medical    O
Center    O
.    O

Anti-CD22    B-Antineoplastic102722458
immunotoxins    I-Antineoplastic102722458
,    O
being    O
tested    O
in    O
hairy    O
cell    O
leukemia    O

AZ2171    O
(    O
cediranib    B-Antineoplastic102722458
)    O
,    O
a    O
multi    O
-    O
targeted    O
tyrosine    O
kinase    O
inhibitor    O
has    O
been    O
shown    O
to    O
have    O
anti    O
-    O
edema    O
effects    O
by    O
reducing    O
the    O
permeability    O
and    O
aiding    O
in    O
vascular    O
normalization    O
.    O

Linsitinib    B-Antineoplastic102722458
(    O
OSI-906    O
)    O
,    O
an    O
inhibitor    O
of    O
IGF-1R    O
in    O
clinical    O
trials    O
for    O
cancer    O
treatment    O

dinaciclib    B-Antineoplastic102722458
(    O
USAN    O
,    O
INN    O
)    O

Bis(chloroethyl)    B-Antineoplastic102722458
ether    I-Antineoplastic102722458
-    O
(    O
CH2ClCH2)2O    O

In    O
pharmacology    O
,    O
hazardous    B-Antineoplastic102722458
drugs    I-Antineoplastic102722458
are    O
drugs    O
that    O
are    O
known    O
to    O
cause    O
harm    O
,    O
which    O
may    O
or    O
may    O
not    O
include    O
"    O
genotoxicity    O
"    O
(    O
the    O
ability    O
to    O
cause    O
a    O
change    O
or    O
mutation    O
in    O
genetic    O
material    O
)    O
.    O

Reolysin    B-Antineoplastic102722458
is    O
a    O
formulation    O
of    O
reovirus    O
that    O
is    O
currently    O
in    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
various    O
cancers    O
.    O

2015    O
–    O
Cotellic    B-Antineoplastic102722458
(    O
cobimetinib    O
)    O
:    O
For    O
use    O
in    O
combination    O
with    O
ZELBORAF    O
(    O
vemurafenib    O
)    O
,    O
to    O
treat    O
a    O
type    O
of    O
skin    O
cancer    O
called    O
melanoma    O
that    O
has    O
spread    O
to    O
other    O
parts    O
of    O
the    O
body    O
or    O
can    O
not    O
be    O
removed    O
by    O
surgery    O
,    O
and    O
that    O
has    O
a    O
certain    O
type    O
of    O
abnormal    O
“    O

Vadimezan    B-Antineoplastic102722458
(    O
also    O
known    O
as    O
or    O
ASA404    B-Antineoplastic102722458
and    O
DMXAA    B-Antineoplastic102722458
)    O
is    O
a    O
tumor    O
-    O
vascular    B-Antineoplastic102722458
disrupting    I-Antineoplastic102722458
agent    I-Antineoplastic102722458
(    O
tumor    O
-    O
VDA    O
)    O
that    O
attacks    O
the    O
blood    O
supply    O
of    O
a    O
cancerous    O
tumor    O
to    O
cause    O
tumor    O
regression    O
.    O

Increased    O
expression    O
of    O
HMGA2    O
increased    O
BER    O
,    O
and    O
allowed    O
cells    O
with    O
increased    O
HMGA2    O
to    O
be    O
resistant    O
to    O
hydroxyurea    B-Antineoplastic102722458
,    O
a    O
chemotherapeutic    O
agent    O
for    O
solid    O
tumors    O
.    O

Hydroxycarbamide    B-Antineoplastic102722458

The    O
primary    O
treatment    O
consists    O
of    O
anagrelide    B-Antineoplastic102722458
or    O
hydroxyurea    B-Antineoplastic102722458
to    O
lower    O
platelet    O
levels    O
.    O

For    O
example    O
,    O
it    O
is    O
used    O
to    O
prepare    O
the    O
drug    O
hydroxyurea    B-Antineoplastic102722458
.    O

Non    O
-    O
biologic    O
systemic    O
treatments    O
frequently    O
used    O
for    O
psoriasis    O
include    O
methotrexate    O
,    O
ciclosporin    O
,    O
hydroxycarbamide    B-Antineoplastic102722458
,    O
fumarates    O
such    O
as    O
dimethyl    O
fumarate    O
,    O
and    O
retinoids    O
.    O

Hydroxyurea    B-Antineoplastic102722458
is    O
a    O
medication    O
that    O
can    O
help    O
to    O
prevent    O
chest    O
syndrome    O
.    O

Only    O
cytotoxic    O
drugs    O
such    O
as    O
busulfan    O
,    O
hydroxyurea    B-Antineoplastic102722458
or    O
interferon    O
-    O
alpha    O
(    O
rIFN-α    O
)    O
were    O
utilized    O
.    O

JCCC    O
scientists    O
developed    O
palbociclib    B-Antineoplastic102722458
(    O
PD    O
0332991    O
)    O
,    O
a    O
breast    O
-    O
cancer    O
drug    O
that    O
was    O
in    O
phase    O
III    O
clinical    O
trials    O
as    O
of    O
2015    O
.    O

Palbociclib    B-Antineoplastic102722458
,    O
doubles    O
PFS    O
of    O
letrozole    O
alone    O

3β-Hydroxysteroid    O
dehydrogenase    O
(    O
3β-HSD    O
)    O
inhibitors    O
such    O
as    O
amphenone    O
B    O
,    O
azastene    O
,    O
cyanoketone    O
,    O
epostane    O
,    O
mitotane    B-Antineoplastic102722458
,    O
and    O
trilostane    O
inhibit    O
the    O
conversion    O
of    O
Δ5    O
-    O
3β-hydroxysteroids    O
into    O
Δ4    O
-    O
3-ketosteroids    O
and    O
thereby    O
inhibit    O
the    O
production    O
of    O
most    O
of    O
the    O
steroid    O
hormones    O
.    O

11β-Hydroxylase    O
(    O
CYP11B1    O
)    O
inhibitors    O
such    O
as    O
amphenone    O
B    O
,    O
etomidate    O
,    O
ketoconazole    O
,    O
metyrapone    O
,    O
mitotane    B-Antineoplastic102722458
,    O
and    O
osilodrostat    O
inhibit    O
the    O
production    O
of    O
the    O
potent    O
corticosteroids    O
cortisol    O
,    O
corticosterone    O
,    O
and    O
aldosterone    O
from    O
the    O
less    O
potent    O
corticosteroids    O
11-deoxycorticosterone    O
and    O
11-deoxycortisol    O
and    O
are    O
used    O
in    O
the    O
diagnosis    O
and    O
treatment    O
of    O
Cushing    O
's    O
syndrome    O
.    O

Aldosterone    O
synthase    O
(    O
CYP11B2    O
)    O
inhibitors    O
such    O
as    O
metyrapone    O
,    O
mitotane    B-Antineoplastic102722458
,    O
and    O
osilodrostat    O
prevent    O
the    O
production    O
of    O
the    O
potent    O
mineralocorticoid    O
aldosterone    O
from    O
the    O
less    O
potent    O
mineralocorticoid    O
corticosterone    O
.    O

Sigma    O
-    O
Tau    O
in    O
collaboration    O
with    O
the    O
non    O
-    O
profit    O
organization    O
Medicines    O
for    O
Malaria    O
Venture    O
(    O
MMV    O
)    O
has    O
developed    O
a    O
new    O
medicine    O
for    O
the    O
treatment    O
of    O
malaria    O
a    O
fixed    O
combination    O
consisting    O
of    O
dihydroartemisinin    O
and    O
piperaquine    O
,    O
judged    O
to    O
be    O
one    O
of    O
the    O
most    O
effective    O
antimalaria    O
medicines    O
available    O
and    O
the    O
best    O
combination    O
containing    O
artemisinin    B-Antineoplastic102722458
.    O

collaborates    O
with    O
Medicines    O
for    O
Malaria    O
Venture    O
(    O
MMV    O
)    O
)    O
,    O
an    O
association    O
supported    O
by    O
the    O
Bill    O
&    O
Melinda    O
Gates    O
Foundation    O
in    O
the    O
development    O
of    O
one    O
of    O
the    O
most    O
efficient    O
antimalaria    O
medicines    O
available    O
,    O
a    O
fixed    O
combination    O
consisting    O
of    O
dihydroartemisinin    O
and    O
piperaquine    O
judged    O
to    O
be    O
the    O
best    O
combination    O
containing    O
artemisinin    B-Antineoplastic102722458
,    O
partly    O
due    O
to    O
the    O
low    O
incidence    O
of    O
side    O
effects    O
;    O

Arteminisinin,    B-Antineoplastic102722458
anti-malarial    I-Antineoplastic102722458
treatment    I-Antineoplastic102722458
:    O
The    O
antimalarial    O
drug    O
of    O
compound    O
artemisinin    B-Antineoplastic102722458
found    O
in    O
"    O
Artemisia    O
annua    O
"    O
,    O
the    O
latter    O
being    O
a    O
plant    O
long    O
used    O
in    O
traditional    O
Chinese    O
medicine    O
,    O
was    O
discovered    O
in    O
1972    O
by    O
Chinese    O
scientists    O
in    O
the    O
People    O
's    O
Republic    O
led    O
by    O
Tu    O
Youyou    O
and    O
has    O
been    O
used    O
to    O
treat    O
multi    O
-    O
drug    O
resistant    O
strains    O
of    O
"    O
Plasmodium    O
falciparum    O
"    O
malaria    O
.    O

It    O
is    O
in    O
the    O
artemisinin    B-Antineoplastic102722458
class    O
of    O
medication    O
.    O

Artemether    O
is    O
an    O
artemisinin    B-Antineoplastic102722458
derivative    O
and    O
the    O
mechanism    O
of    O
action    O
for    O
artemisinins    O
is    O
unknown    O
.    O

Artemether    O
is    O
a    O
methyl    O
ether    O
derivative    O
of    O
artemisinin    B-Antineoplastic102722458
,    O
which    O
is    O
a    O
peroxide    O
-    O
containing    O
lactone    O
isolated    O
from    O
the    O
antimalarial    O
plant    O
"    O
Artemisia    O
annua    O
"    O
.    O

It    O
is    O
in    O
the    O
artemisinin    B-Antineoplastic102722458
class    O
of    O
medication    O
.    O

In    O
facilities    O
where    O
long    O
-    O
term    O
care    O
is    O
not    O
appropriate    O
,    O
artesunate    O
may    O
be    O
given    O
as    O
a    O
single    O
intramuscular    O
injection    O
or    O
by    O
rectal    O
route    O
(    O
children    O
s    O
from    O
Artemisinin    B-Antineoplastic102722458
that    O
is    O
water    O
-    O
soluble    O
.    O

Artemisinin    B-Antineoplastic102722458
,    O
Tu    O
Youyou    O
,    O
Project    O
523    O
,    O
Dihydroartemisinin    O
.    O

Artemisinin    B-Antineoplastic102722458
are    O
sesquiterpene    O
lactones    O
isolated    O
from    O
"    O
Artemisia    O
annua    O
"    O
,    O
a    O
Chinese    O
traditional    O
medicine    O
.    O

Characterisation    O
and    O
genetic    O
mapping    O
of    O
traits    O
responsible    O
for    O
production    O
of    O
artemisinin    B-Antineoplastic102722458
in    O
"    O
Artemisia    O
annua    O
"    O
has    O
enabled    O
development    O
of    O
F1    O
hybrid    O
seed    O
that    O
can    O
deliver    O
a    O
robust    O
source    O
of    O
this    O
vital    O
antimalarial    O
medication    O
for    O
the    O
developing    O
countries    O
.    O

His    O
work    O
also    O
helped    O
in    O
the    O
genetic    O
improvement    O
which    O
yielded    O
higher    O
levels    O
of    O
artemisinin    B-Antineoplastic102722458
in    O
Artemisia    O
annua    O
(    O
Sweet    O
wormwood    O
)    O
and    O
essential    O
oil    O
in    O
Mentha    O
arvensis    O
(    O
Wild    O
mint    O
)    O
.    O

Resistance    O
to    O
recently    O
developed    O
drugs    O
such    O
as    O
artemisinin    B-Antineoplastic102722458
has    O
also    O
been    O
reported    O
.    O

Panobinostat    B-Antineoplastic102722458
(    O
LBH589    O
)    O
is    O
in    O
clinical    O
trials    O
for    O
various    O
cancers    O
including    O
a    O
phase    O
III    O
trial    O
for    O
cutaneous    O
T    O
cell    O
lymphoma    O
(    O
CTCL    O
)    O
.    O

His    O
cancer    O
was    O
shrinking    O
as    O
a    O
result    O
of    O
treatment    O
using    O
an    O
experimental    O
HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
,    O
LBH-589    B-Antineoplastic102722458
.    O

Dose-dense    B-Antineoplastic102722458
chemotherapy    I-Antineoplastic102722458
is    O
a    O
chemotherapy    O
treatment    O
plan    O
in    O
which    O
drugs    O
are    O
given    O
with    O
less    O
time    O
between    O
treatments    O
than    O
in    O
a    O
standard    O
chemotherapy    O
treatment    O
plan    O
.    O

Vintafolide    B-Antineoplastic102722458
is    O
a    O
small    O
molecule    O
drug    O
conjugate    O
consisting    O
of    O
a    O
small    O
molecule    O
targeting    O
the    O
folate    O
receptor    O
.    O

The    O
most    O
advanced    O
SMDC    O
is    O
vintafolide    B-Antineoplastic102722458
,    O
a    O
derivative    O
of    O
the    O
anti    O
-    O
mitotic    O
chemotherapy    O
drug    O
vinblastine    O
which    O
is    O
chemically    O
linked    O
to    O
folic    O
acid    O
.    O

Vascular-targeting    B-Antineoplastic102722458
agent    I-Antineoplastic102722458
,    O
anti    O
-    O
cancer    O
drug    O

DHA-paclitaxel    B-Antineoplastic102722458
(    O
or    O
Taxoprexin    O
)    O
is    O
an    O
investigational    O
drug    O
(    O
from    O
Protarga    O
Inc    O
)    O
made    O
by    O
linking    O
paclitaxel    O
to    O
docosahexaenoic    O
acid    O
(    O
DHA    O
)    O
,    O
a    O
fatty    O
acid    O
that    O
is    O
easily    O
taken    O
up    O
by    O
tumor    O
cells    O
;    O
the    O
DHA    O
-    O
paclitaxel    O
“    O
appears    O
not    O
to    O
be    O
cytotoxic    O
until    O
the    O
bond    O
with    O
DHA    O
is    O
cleaved    O
within    O
the    O
cell    O
.    O
”    O
The    O
advantage    O
of    O
DHA    O
-    O
paclitaxel    O
over    O
paclitaxel    O
is    O
DHA    O
-    O
paclitaxel    O
’s    O
ability    O
to    O
carry    O
much    O
higher    O
concentrations    O
of    O
paclitaxel    O
to    O
the    O
cells    O
,    O
which    O
are    O
maintained    O
for    O
longer    O
periods    O
in    O
the    O
tumor    O
cells    O
,    O
thus    O
increasing    O
their    O
action    O
.    O

Photosensitizers    O
commercially    O
available    O
for    O
clinical    O
use    O
include    O
Allumera    O
,    O
Photofrin    O
,    O
Visudyne    O
,    O
Levulan    O
,    O
Foscan    O
,    O
Metvix    O
,    O
Hexvix    O
,    O
Cysview    O
and    O
Laserphyrin    O
,    O
with    O
others    O
in    O
development    O
,    O
e.g.    O
Antrin    O
,    O
Photochlor    O
,    O
Photosens    O
,    O
Photrex    O
,    O
Lumacan    O
,    O
Cevira    O
,    O
Visonac    O
,    O
BF-200    O
ALA    O
,    O
Amphinex    B-Antineoplastic102722458
and    O
Azadipyrromethenes    O
.    O

Many    O
of    O
these    O
products    O
,    O
such    O
as    O
Firazyr®    O
,    O
Xofigo    B-Antineoplastic102722458
,    O
Tracleer®    O
,    O
are    O
breakthrough    O
therapies    O
addressing    O
life    O
-    O
threatening    O
diseases    O
.    O

Xofigo    B-Antineoplastic102722458
developed    O
by    O
Algeta    O
for    O
treatment    O
of    O
bone    O
metastasis    O
in    O
prostate    O
cancer    O
.    O

Radium-223    B-Antineoplastic102722458
chloride    O
,    O
strontium-89    O
chloride    O
and    O
samarium-153    O
EDTMP    O
are    O
used    O
to    O
treat    O
secondary    O
cancer    O
in    O
the    O
bones    O
.    O

Acetalated    O
dextran    O
's    O
unique    O
properties    O
has    O
also    O
resulted    O
in    O
its    O
application    O
in    O
polymeric    O
micro    O
/    O
nanoparticles    O
for    O
use    O
in    O
formulating    O
the    O
anti    O
-    O
infective    O
OSU-03012    B-Antineoplastic102722458
for    O
use    O
against    O
"    O
Leishmania    O
donovani","Salmonella    O
enterica    O
"    O
,    O
and    O
"    O
Francisella    O
tularensis    O
"    O
.    O

Biricodar    B-Antineoplastic102722458
(    O
INN    O
,    O
codename    O
VX-710    B-Antineoplastic102722458
,    O
marketed    O
as    O
the    O
dicitrate    O
salt    O
under    O
the    O
trade    O
name    O
Incel    B-Antineoplastic102722458
)    O
is    O
a    O
pharmaceutical    O
drug    O
released    O
by    O
Vertex    O
Pharmaceuticals    O
in    O
1999    O
to    O
help    O
treat    O
ovarian    O
cancer    O
patients    O
.    O

Volasertib    B-Antineoplastic102722458
(    O
also    O
known    O
as    O
BI    O
6727    O
)    O
is    O
an    O
experimental    O
small    O
molecule    O
inhibitor    O
of    O
the    O
PLK1    O
(    O
polo    O
-    O
like    O
kinase    O
1    O
)    O
protein    O
being    O
developed    O
by    O
Boehringer    O
Ingelheim    O
for    O
use    O
as    O
an    O
anti    O
-    O
cancer    O
agent    O
.    O

Penostatin    B-Antineoplastic102722458
A    I-Antineoplastic102722458
is    O
a    O
cytotoxic    O
metabolite    O
produced    O
by    O
"    O
Penicillium    O
"    O
.    O

Some    O
sources    O
explicitly    O
exclude    O
the    O
triazenes    O
(    O
dacarbazine    O
,    O
mitozolomide    B-Antineoplastic102722458
,    O
temozolomide    B-Antineoplastic102722458
)    O
from    O
the    O
nonclassical    O
category    O
.    O

Exisulind    B-Antineoplastic102722458
(    O
tentative    O
trade    O
name    O
Aptosyn    B-Antineoplastic102722458
)    O
is    O
an    O
antineoplastic    O
agent    O
.    O

Ribonucleotide    B-Antineoplastic102722458
reductase    I-Antineoplastic102722458
inhibitors    I-Antineoplastic102722458
are    O
a    O
family    O
of    O
anti    O
-    O
cancer    O
drugs    O
that    O
interfere    O
with    O
the    O
growth    O
of    O
tumor    O
cells    O
by    O
blocking    O
the    O
formation    O
of    O
deoxyribonucleotides    O
(    O
building    O
blocks    O
of    O
DNA    O
)    O
.    O

Talampanel    B-Antineoplastic102722458

Imexon    B-Antineoplastic102722458

ADH-1    B-Antineoplastic102722458
(    O
brand    O
name    O
Exherin    B-Antineoplastic102722458
)    O
is    O
a    O
small    O
,    O
cyclic    O
pentapeptide    O
vascular    O
-    O
targeting    O
drug    O
.    O

Mertansine    B-Antineoplastic102722458
,    O
a    O
maytansinoid    O
cytotoxic    O
agent    O
used    O
in    O
trastuzumab    O
emtansine    O
and    O
other    O
antibody    O
-    O
drug    O
conjugates    O

Mertansine    B-Antineoplastic102722458
/    O
emtansine    B-Antineoplastic102722458
(    O
DM1    O
)    O

Vorinostat    B-Antineoplastic102722458
was    O
licensed    O
by    O
the    O
U.S.    O
FDA    O
in    O
October    O
2006    O
for    O
the    O
treatment    O
of    O
cutaneous    O
T    O
cell    O
lymphoma    O
(    O
CTCL    O
)    O
.    O

Common    O
treatments    O
include    O
simple    O
sunlight    O
,    O
ultraviolet    O
light    O
(    O
mainly    O
NB    O
-    O
UVB    O
312    O
nm    O
)    O
,    O
topical    O
steroids    O
,    O
topical    O
and    O
systemic    O
chemotherapies    O
,    O
local    O
superficial    O
radiotherapy    O
,    O
the    O
histone    B-Antineoplastic102722458
deacetylase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
vorinostat    B-Antineoplastic102722458
,    O
total    O
skin    O
electron    O
beam    O
radiation    O
,    O
photopheresis    O
and    O
systemic    O
therapies    O
(    O
e.g.    O
interferons    O
,    O
retinoids    O
,    O
rexinoids    O
)    O
or    O
biological    O
therapies    O
.    O

Suberoylanilide    B-Antineoplastic102722458
hydroxamic    I-Antineoplastic102722458
acid    I-Antineoplastic102722458
(    O
SAHA    O
)    O
(    O
a    O
HDAC    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
)    O
increases    O
expression    O
of    O
aquaporin-3    O
in    O
normal    O
skin    O
cells    O
(    O
keratinocytes    O
)    O
.    O

Studies    O
with    O
histone    O
deactylase    O
complex    O
inhibitors    O
like    O
SAHA    B-Antineoplastic102722458
,    O
toluene    O
,    O
garcinol    O
,    O
trichostatin    O
A    O
and    O
sodium    O
butyrate    O
have    O
shown    O
that    O
acetylation    O
is    O
important    O
for    O
the    O
synaptic    O
plasticity    O
of    O
the    O
brain    O
;    O
by    O
inhibiting    O
deactylase    O
complexes    O
total    O
acetylation    O
rates    O
in    O
the    O
brain    O
increased    O
leading    O
to    O
increased    O
rates    O
of    O
transcription    O
and    O
enhanced    O
memory    O
consolidation    O
.    O

SAHA    B-Antineoplastic102722458
,    O
a    O
HDAC    O
inhibitor    O
,    O
increased    O
freezing    O
of    O
HDAC2    O
OE    O
mice    O
in    O
contextual    O
fear    O
and    O
tone    O
dependent    O
experiments    O
,    O
but    O
did    O
not    O
effect    O
HDAC2    O
KO    O
mice    O
suggesting    O
HDAC2    O
is    O
major    O
target    O
of    O
SAHA    O

One    O
example    O
of    O
this    O
is    O
the    O
loss    O
of    O
estrogen    O
receptor    O
(    O
ER    O
)    O
and    O
progesterone    O
receptor    O
(    O
PR    O
)    O
upon    O
anti-estrogen    B-Antineoplastic102722458
treatment    I-Antineoplastic102722458
of    O
breast    O
cancer    O

In    O
the    O
same    O
study    O
,    O
spironolactone    O
was    O
administered    O
to    O
rats    O
and    O
found    O
to    O
produce    O
mixed    O
estrogenic    O
and    O
antiestrogen    B-Antineoplastic102722458
or    O
selective    O
estrogen    O
receptor    O
modulator    O
(    O
SERM)-like    O
effects    O
that    O
were    O
described    O
as    O
very    O
similar    O
to    O
those    O
of    O
tamoxifen    O
.    O

antiestrogen    B-Antineoplastic102722458
such    O
as    O
Tamoxifen    O

Examples    O
of    O
progonadotropic    O
drugs    O
include    O
gonadotropin    O
-    O
releasing    O
hormone    O
(    O
GnRH    O
)    O
agonists    O
when    O
administered    O
in    O
a    O
pulsatile    O
(    O
as    O
opposed    O
to    O
continuous    O
)    O
manner    O
,    O
antiestrogen    B-Antineoplastic102722458
such    O
as    O
tamoxifen    O
,    O
clomifene    O
,    O
fulvestrant    O
,    O
and    O
aromatase    O
inhibitors    O
like    O
anastrozole    O
,    O
and    O
,    O
only    O
in    O
men    O
,    O
pure    O
antiandrogens    O
such    O
as    O
flutamide    O
,    O
bicalutamide    O
,    O
and    O
enzalutamide    B-Antineoplastic102722458
.    O

Whereas    O
zuclomifene    O
is    O
more    O
estrogenic    O
,    O
enclomifene    O
is    O
more    O
antiestrogen    B-Antineoplastic102722458
.    O

Whereas    O
zuclomifene    O
is    O
described    O
as    O
mildly    O
estrogenic    O
,    O
enclomifene    O
is    O
described    O
as    O
antiestrogen    B-Antineoplastic102722458
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    B-Antineoplastic102722458
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Due    O
to    O
its    O
potent    O
antigonadotropic    O
activity    O
,    O
NOMAC    O
has    O
strong    O
functional    O
antiandrogenic    O
and    O
antiestrogen    B-Antineoplastic102722458
effects    O
when    O
administered    O
at    O
sufficiently    O
high    O
dosages    O
.    O

The    O
2014    O
-    O
15    O
list    O
of    O
NCAA    O
banned    O
drugs    O
includes    O
the    O
following    O
classes    O
:    O
stimulants    O
(    O
except    O
for    O
phenylephrine    O
and    O
pseudoephedrine    O
,    O
which    O
are    O
permitted    O
)    O
;    O
anabolic    O
agents    O
;    O
diuretics    O
and    O
other    O
masking    O
agents    O
;    O
"    O
street    O
drugs    O
"    O
(    O
the    O
NCAA    O
gives    O
as    O
examples    O
heroin    O
,    O
marijuana    O
,    O
tetrahydrocannabinol    O
(    O
THC    O
)    O
,    O
and    O
synthetic    O
cannabinoids    O
)    O
;    O
peptide    O
hormones    O
and    O
analogues    O
;    O
anti-estrogen    B-Antineoplastic102722458
,    O
and    O
beta-2    O
agonists    O
.    O

The    O
compound    O
has    O
shown    O
some    O
"    O
in    O
vitro    O
"    O
anticancer    B-Antineoplastic102722458
,    O
antiestrogenic    B-Antineoplastic102722458
,    O
immunomodulatory    O
,    O
and    O
anti    O
-    O
amoebic    O
activity    O
(    O
particularly    O
against    O
"    O
Entamoeba    O
histolytica    O
"    O
)    O
.    O

Upon    O
reassessment    O
many    O
decades    O
later    O
,    O
the    O
compound    O
was    O
found    O
to    O
bind    O
only    O
weakly    O
to    O
the    O
estrogen    O
receptors    O
,    O
and    O
,    O
unexpectedly    O
,    O
did    O
not    O
actually    O
have    O
functional    O
activity    O
as    O
an    O
estrogen    O
or    O
antiestrogen    B-Antineoplastic102722458
"    O
in    O
vitro    O
"    O
or    O
"    O
in    O
vivo    O
"    O
.    O

It    O
is    O
a    O
potent    O
estrogen    O
similarly    O
to    O
estrone    O
,    O
and    O
it    O
has    O
been    O
suggested    O
that    O
the    O
ratio    O
of    O
16α-hydroxyestrone    O
to    O
2-hydroxyestrone    O
,    O
the    O
latter    O
being    O
much    O
less    O
estrogenic    O
in    O
comparison    O
and    O
even    O
antiestrogen    B-Antineoplastic102722458
in    O
the    O
presence    O
of    O
more    O
potent    O
estrogens    O
like    O
estradiol    O
,    O
may    O
be    O
involved    O
in    O
the    O
pathophysiology    O
of    O
breast    O
cancer    O
.    O

Prinomastat    B-Antineoplastic102722458
(    O
code    O
name    O
AG-3340    O
)    O
is    O
a    O
matrix    O
metalloproteinase    O
(    O
MMP    O
)    O
inhibitor    O
with    O
specific    O
selectivity    O
for    O
MMPs    O
2    O
,    O
3    O
,    O
9    O
,    O
13    O
,    O
and    O
14    O
.    O

Tivozanib    B-Antineoplastic102722458
(    O
AV-951    O
)    O
is    O
an    O
oral    O
VEGF    O
receptor    O
tyrosine    O
kinase    O
inhibitor    O
.    O

Allovectin-7    B-Antineoplastic102722458
is    O
a    O
substance    O
that    O
is    O
being    O
studied    O
as    O
a    O
gene    O
therapy    O
agent    O
in    O
the    O
treatment    O
of    O
cancer    O
,    O
such    O
as    O
malignant    O
melanoma    O
.    O

O6-Benzylguanine    B-Antineoplastic102722458
,    O
a    O
drug    O
which    O
depletes    O
O6-alkylguanine    O
-    O
DNA    O
alkyltransferase    O
by    O
virtue    O
of    O
its    O
similarity    O
to    O
the    O
DNA    O
repair    O
protein    O
's    O
target    O
lesion    O
.    O

Troxacitabine    B-Antineoplastic102722458
(    O
brand    O
name    O
Troxatyl    B-Antineoplastic102722458
)    O
is    O
a    O
nucleoside    O
analogue    O
with    O
anticancer    O
activity    O
.    O

mitoguazone    B-Antineoplastic102722458
(    O
INN    O
)    O

Tariquidar    B-Antineoplastic102722458
(    O
INN    O
/    O
USAN    O
)    O
is    O
a    O
P    O
-    O
glycoprotein    O
inhibitor    O
undergoing    O
research    O
as    O
an    O
adjuvant    O
against    O
multidrug    O
resistance    O
in    O
cancer    O
.    O

Anthramycin    B-Antineoplastic102722458

Idelalisib    B-Antineoplastic102722458
is    O
a    O
PI3    O
K    O
inhibitor    O
.    O
and    O
is    O
taken    O
orally    O
.    O

Competition    O
is    O
expected    O
from    O
other    O
drugs    O
such    O
as    O
Imbruvica    O
(    O
ibrutinib    B-Antineoplastic102722458
)    O
and    O
Zydelig    O
(    O
idelalisib    B-Antineoplastic102722458
)    O
,    O
both    O
of    O
which    O
were    O
also    O
approved    O
in    O
2014    O
to    O
treat    O
CLL    O
(    O
chronic    O
lymphocytic    O
leukemia    O
)    O
.    O

In    O
mouse    O
studies    O
,    O
these    O
symptoms    O
can    O
be    O
avoided    O
through    O
the    O
use    O
of    O
alternate    O
dosing    O
regimens    O
or    O
analogs    O
such    O
as    O
everolimus    B-Antineoplastic102722458
or    O
temsirolimus    B-Antineoplastic102722458
.    O

Other    O
mTOR    O
inhibitors    O
,    O
such    O
as    O
temsirolimus    B-Antineoplastic102722458
(    O
CCI-779    O
)    O
or    O
everolimus    B-Antineoplastic102722458
(    O
RAD001    O
)    O
,    O
are    O
being    O
tested    O
for    O
use    O
in    O
cancers    O
such    O
as    O
glioblastoma    O
multiforme    O
and    O
mantle    O
cell    O
lymphoma    O
.    O

After    O
several    O
studies    O
conclusively    O
linked    O
mTOR    O
inhibitors    O
to    O
remission    O
in    O
TSC    O
tumors    O
,    O
specifically    O
subependymal    O
giant    O
-    O
cell    O
astrocytomas    O
in    O
children    O
and    O
angiomyolipomas    O
in    O
adults    O
,    O
many    O
US    O
doctors    O
began    O
prescribing    O
sirolimus    O
(    O
Wyeth    O
's    O
Rapamune    O
)    O
and    O
everolimus    B-Antineoplastic102722458
(    O
Novartis    O
's    O
RAD001    O
)    O
to    O
TSC    O
patients    O
off    O
-    O
label    O
.    O

Everolimus    B-Antineoplastic102722458

Everolimus    B-Antineoplastic102722458
(    O
INN    O
)    O
(    O
earlier    O
code    O
name    O
RAD001    B-Antineoplastic102722458
)    O
is    O
the    O
40-"O"-(2-hydroxyethyl    O
)    O
derivative    O
of    O
sirolimus    O
and    O
works    O
similarly    O
to    O
sirolimus    O
as    O
an    O
inhibitor    O
of    O
mammalian    O
target    O
of    O
rapamycin    O
(    O
mTOR    O
)    O
.    O

In    O
1968    O
GSML    O
provided    O
the    O
first    O
specimens    O
of    O
the    O
bryozoan    O
"    O
Bugula    O
neritina    O
"    O
used    O
by    O
the    O
National    O
Cancer    O
Institute    O
(    O
NCI    O
)    O
to    O
develop    O
the    O
bryostatin    B-Antineoplastic102722458
family    O
of    O
drugs    O
used    O
for    O
treatment    O
of    O
cancer    O
,    O
HIV    O
,    O
Alzheimer    O
’s    O
disease    O
and    O
strokes    O
.    O

Early    O
on    O
at    O
Iowa    O
State    O
University    O
Clardy    O
established    O
important    O
collaborations    O
with    O
Bill    O
Fenical    O
,    O
John    O
Faulkner    O
and    O
Paul    O
Scheuer    O
,    O
which    O
led    O
to    O
the    O
structure    O
elucidation    O
of    O
numerous    O
marine    O
natural    O
products    O
such    O
as    O
the    O
anticancer    O
agent    O
bryostatin    B-Antineoplastic102722458
,    O
the    O
insecticidal    O
and    O
antifungal    O
jaspamide    O
,    O
diazonamide    O
A    O
and    O
B    O
,    O
and    O
many    O
others    O
.    O

1-Bromopropane    B-Antineoplastic102722458
(    O
"    O
n    O
"-    O
propyl    O
bromide    O
)    O

Pegdinetanib    B-Antineoplastic102722458
(    O
USAN    O
;    O
planned    O
trade    O
name    O
Angiocept    B-Antineoplastic102722458
)    O
is    O
an    O
investigational    O
anti    O
-    O
cancer    O
drug    O
that    O
acts    O
as    O
a    O
selective    O
antagonist    O
of    O
vascular    O
endothelial    O
growth    O
factor    O
receptor    O
2    O
(    O
VEGFR-2    O
)    O
,    O
hindering    O
vascularization    O
of    O
tumors    O
.    O

elsamitrucin    B-Antineoplastic102722458
(    O
INN    O
)    O

enocitabine    B-Antineoplastic102722458
(    O
INN    O
)    O

chloromethyl    B-Antineoplastic102722458
methyl    I-Antineoplastic102722458
ether    I-Antineoplastic102722458
-    O
CH2ClOMe    O

Chloromethyl    B-Antineoplastic102722458
methyl    I-Antineoplastic102722458
ether    I-Antineoplastic102722458

carzelesin    B-Antineoplastic102722458
(    O
INN    O
)    O

Adozelesin    B-Antineoplastic102722458
is    O
an    O
experimental    O
antitumor    O
drug    O
of    O
the    O
duocarmycin    B-Antineoplastic102722458
class    O
.    O

The    O
next    O
landmark    O
discovery    O
came    O
with    O
the    O
detection    O
of    O
rebeccamycin    B-Antineoplastic102722458
(    O
REB    O
)    O
in    O
a    O
sample    O
of    O
"    O
Lechevalieria    O
aerocolonigenes    O
"    O
,    O
again    O
in    O
soil    O
,    O
but    O
this    O
time    O
in    O
a    O
sample    O
from    O
Panama    O
.    O

Lechevalieria    O
aerocolonigenes    O
"    O
produces    O
rebeccamycin    B-Antineoplastic102722458
.    O

Anagrelide    B-Antineoplastic102722458
(    O
Agrylin    O
/    O
Xagrid    O
,    O
Shire    O
and    O
Thromboreductin    O
,    O
AOP    O
Orphan    O
Pharmaceuticals    O
AG    O
)    O
is    O
a    O
drug    O
used    O
for    O
the    O
treatment    O
of    O
essential    O
thrombocytosis    O
(    O
ET    O
;    O
essential    O
thrombocythemia    O
)    O
,    O
or    O
overproduction    O
of    O
blood    O
platelets    O
.    O

The    O
primary    O
treatment    O
consists    O
of    O
anagrelide    B-Antineoplastic102722458
or    O
hydroxyurea    B-Antineoplastic102722458
to    O
lower    O
platelet    O
levels    O
.    O

Therapies    O
for    O
metastatic    O
melanoma    O
include    O
the    O
biologic    O
immunotherapy    O
agents    O
ipilimumab    O
,    O
pembrolizumab    B-Antineoplastic102722458
,    O
and    O
nivolumab    O
;    O
BRAF    O
inhibitors    O
,    O
such    O
as    O
vemurafenib    O
and    O
dabrafenib    O
;    O
and    O
a    O
MEK    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
trametinib    O
.    O

MEK    B-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
(    O
trametinib    O
,    O
MEK162    O
)    O
are    O
used    O
in    O
experiments    O
,    O
often    O
in    O
combination    O
with    O
BRAF    O
inhibitors    O
to    O
treat    O
melanoma    O

Molgramostim    B-Antineoplastic102722458
is    O
a    O
recombinant    O
granulocyte    O
macrophage    O
colony    O
-    O
stimulating    O
factor    O
which    O
functions    O
as    O
an    O
immunostimulator    O
.    O

It    O
is    O
a    O
metabolite    O
of    O
lucanthone    B-Antineoplastic102722458
.    O

Minamestane    B-Antineoplastic102722458

Discodermolide    B-Antineoplastic102722458

Discodermolide    B-Antineoplastic102722458

As    O
of    O
2017    O
,    O
the    O
combination    O
of    O
epacadostat    O
with    O
pembrolizumab    B-Antineoplastic102722458
(    O
Keytruda    O
)    O
was    O
being    O
investigated    O
by    O
Incyte    O
and    O
Merck    O
&    O
Co.    O
in    O
several    O
cancers    O
,    O
as    O
was    O
the    O
combination    O
of    O
epacadostat    O
with    O
nivolumab    O
(    O
Opdivo    O
)    O
by    O
Incyte    O
and    O
Bristol    O
Myers    O
Squibb    O
.    O

Promising    O
clinical    O
trial    O
results    O
made    O
public    O
in    O
2012    O
caused    O
excitement    O
among    O
industry    O
analysts    O
and    O
in    O
the    O
mainstream    O
media    O
;    O
PD-1    O
was    O
being    O
avidly    O
pursued    O
as    O
a    O
biological    O
target    O
at    O
that    O
time    O
,    O
with    O
companies    O
including    O
Merck    O
with    O
pembrolizumab    B-Antineoplastic102722458
(    O
Keytruda    O
)    O
,    O
Roche    O
(    O
via    O
its    O
subsidiary    O
Genentech    O
)    O
with    O
atezolizumab    O
,    O
GlaxoSmithKline    O
in    O
collaboration    O
with    O
the    O
Maryland    O
biotech    O
company    O
Amplimmune    O
;    O
and    O
Teva    O
in    O
collaboration    O
with    O
the    O
Israeli    O
biotech    O
company    O
CureTech    O
competing    O
.    O

Whereas    O
these    O
reports    O
were    O
extremely    O
rare    O
throughout    O
the    O
20th    O
century    O
,    O
the    O
clinical    O
use    O
of    O
immune    O
checkpoint    O
blocking    O
antibodies    O
such    O
as    O
ipilimumab    O
or    O
pembrolizumab    B-Antineoplastic102722458
has    O
greatly    O
increased    O
the    O
number    O
of    O
abscopally    O
responding    O
patients    O
in    O
selected    O
groups    O
of    O
patients    O
such    O
as    O
those    O
with    O
metastatic    O
melanoma    O
.    O

Since    O
around    O
2010    O
inhibitory    O
checkpoint    O
molecules    O
have    O
been    O
increasingly    O
considered    O
as    O
new    O
targets    O
for    O
cancer    O
immunotherapies    O
due    O
to    O
the    O
effectiveness    O
of    O
two    O
checkpoint    O
inhibitor    O
drugs    O
that    O
were    O
initially    O
indicated    O
for    O
advanced    O
melanoma    O
-    O
Yervoy    O
,    O
from    O
Bristol    O
-    O
Myers    O
Squibb    O
,    O
and    O
Keytruda    B-Antineoplastic102722458
,    O
from    O
Merck    O
.    O

Belinostat    B-Antineoplastic102722458
(    O
trade    O
name    O
Beleodaq    B-Antineoplastic102722458
,    O
previously    O
known    O
as    O
PXD101    B-Antineoplastic102722458
)    O
is    O
a    O
histone    B-Antineoplastic102722458
deacetylase    I-Antineoplastic102722458
inhibitor    I-Antineoplastic102722458
drug    O
developed    O
by    O
TopoTarget    O
for    O
the    O
treatment    O
of    O
hematological    O
malignancies    O
and    O
solid    O
tumors    O
.    O

Ombrabulin    O
is    O
a    O
combretastatin    B-Antineoplastic102722458
A-4    I-Antineoplastic102722458
derivative    O
that    O
exerts    O
its    O
antitumor    O
effect    O
by    O
disrupting    O
the    O
formation    O
of    O
blood    O
vessels    O
needed    O
for    O
tumor    O
growth    O
.    O

fludarabine    O
,    O
cladribine    O
,    O
gemcitabine    O
,    O
tezacitabine    O
,    O
and    O
triapine    B-Antineoplastic102722458

Selumetinib    B-Antineoplastic102722458
(    O
AZD6244    B-Antineoplastic102722458
)    O
is    O
a    O
drug    O
that    O
was    O
discovered    O
by    O
Array    O
BioPharma    O
and    O
was    O
licensed    O
to    O
AstraZeneca    O
.    O


